Journal article
Clindamycin adjunctive therapy for severe Staphylococcus aureus treatment evaluation (CASSETTE) - An open-labelled pilot randomized controlled trial
AJ Campbell, R Dotel, M Braddick, PN Britton, DP Eisen, JR Francis, S Lynar, B McMullan, N Meagher, J Nelson, MVN O'Sullivan, DJ Price, JO Robinson, A Whelan, SYC Tong, AC Bowen, JS Davis
Jac Antimicrobial Resistance | Published : 2022
Abstract
Background: Combination antibiotic therapy with an antitoxin agent, such as clindamycin, is included in some guidelines for severe, toxin-mediated Staphylococcus aureus infections. The evidence to support this practice is currently limited to in vitro, animal and observational human case-series data, with no previous randomized controlled trials (RCTs). Objectives: This pilot RCT aimed to determine the feasibility of conducting a clinical trial to examine if adjunctive clindamycin with standard therapy has greater efficacy than standard therapy alone for S. aureus infections. Methods: We performed an investigator-initiated, open-label, multicentre, pilot RCT (ACTRN12617001416381p) in adults ..
View full abstractGrants
Awarded by National Health and Medical Research Council
Funding Acknowledgements
This work was supported by a National Health and Medical Research Council HOT NORTH grant (grant number 1131932), a Telethon Kids Institute, Wesfarmers Centre for Vaccines and Infectious Diseases Seed Fund grant, a National Health and Medical Research Council PhD scholarship to A.J.C (grant number APP1133670), National Health and Medical Research Council fellowship to A.C.B (grant number APP1175509) and a National Health and Medical Research Council fellowship to S.Y.C.T. (grant number 1145033).